Novel HDAC Inhibitor Hits Main Goal in Unresectable Melanoma Trial

(MedPage Today) -- Progression-free survival (PFS) in unresectable melanoma improved significantly with the addition of an investigational histone deacetylase (HDAC) inhibitor to immunotherapy, a randomized trial showed. Median PFS increased from...